Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Medicis Pharmaceutical (MRX) Stock Forecast & Price Target

Medicis Pharmaceutical logo
Get the Latest News and Ratings for MRX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medicis Pharmaceutical and its competitors.

Sign Up

MRX Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$31.75$31.00$26.71N/A
Forecasted Upside5.20% Upside6.24% Upside15.00% UpsideN/A
Consensus Rating
Buy
Buy
Buy
N/A

MRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Medicis Pharmaceutical Stock vs. The Competition

TypeMedicis PharmaceuticalFinance CompaniesS&P 500
Consensus Rating Score
3.11
2.50
2.51
Consensus RatingBuyHoldModerate Buy
Predicted Upside5.20% Upside18.66% Upside14.53% Upside
News Sentiment Rating
Neutral News

See Recent MRX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/20/2024Keefe, Bruyette & Woods
4 of 5 stars
 Boost TargetOutperform ➝ Outperform$33.00 ➝ $36.00+25.00%
12/9/2024Barclays
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$32.00 ➝ $35.00+12.14%
11/21/2024Hsbc Global Res
0 of 5 stars
C. Gomez-Lopez
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
11/21/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$33.00+14.15%
11/8/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Moley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$30.00 ➝ $32.00+12.52%
11/6/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$34.00+24.77%
5/20/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$33.00+72.96%
5/20/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$27.00+41.51%
5/20/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$24.00+25.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:41 AM ET.


MRX Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Medicis Pharmaceutical is $31.75, with a high forecast of $36.00 and a low forecast of $24.00.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medicis Pharmaceutical in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRX shares.

According to analysts, Medicis Pharmaceutical's stock has a predicted upside of 5.20% based on their 12-month stock forecasts.

Over the previous 90 days, Medicis Pharmaceutical's stock had 1 upgrade by analysts.

Medicis Pharmaceutical has been rated by research analysts at Barclays, Citigroup, Hsbc Global Res, HSBC, Keefe, Bruyette & Woods, and Piper Sandler in the past 90 days.

Analysts like Medicis Pharmaceutical more than other "finance" companies. The consensus rating for Medicis Pharmaceutical is Buy while the average consensus rating for "finance" companies is Hold. Learn more on how MRX compares to other companies.


This page (NYSE:MRX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners